Business Context and Reporting Period
Company: BioRestorative Therapies, Inc. (BRTX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: BRTX develops therapeutic products using adult stem cells, focusing on the BRTX-100 candidate for lumbar disc disorders (Phase 2 clinical trial ongoing) and the ThermoStem Program for metabolic disorders. The company also pursues a biocosmeceuticals business line.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $11,800 | $233,600 | $340,100 | $357,700 |
| Net Loss | $(3,038,277) | $(1,091,416) | $(11,034,339) | $(7,343,233) |
| Net Loss Per Share (Basic/Diluted) | $(0.33) | $(0.13) | $(1.26) | $(0.96) |
| Operating Expenses | $3,710,241 | $2,502,350 | $12,139,724 | $9,198,019 |
| Cash and Cash Equivalents | $602,444 (as of Sept 30, 2025) | |||
| Marketable Securities | $3,887,383 (as of Sept 30, 2025) | |||
| Working Capital | $1,271,781 (as of Sept 30, 2025) | |||
| Warrant Liabilities | $1,968,315 (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Q3 2025 revenue dropped 95% compared to Q3 2024, primarily due to the cessation of cosmetic product sales revenue ($0 vs. $230,700) which was present in the prior year. Royalty revenue increased slightly to $11,800.
- Increased Operating Loss: Net loss for Q3 2025 widened to $3.04 million from $1.09 million in Q3 2024. YTD 2025 net loss was $11.03 million compared to $7.34 million in YTD 2024.
- R&D Expense Surge: Research and development expenses increased 78.5% in Q3 2025 ($2.59M vs. $1.45M) and 49.2% YTD ($7.47M vs. $5.00M). This is driven by recruitment and costs associated with the Phase 2 clinical trial for BRTX-100.
- Liquidity Reduction: Working capital decreased significantly from $7.40 million at year-end 2024 to $1.27 million at September 30, 2025. Marketable securities declined from $10.18 million to $3.89 million as the company sold assets to fund operations.
- Financing Activity: The company raised approximately $2.0 million in gross proceeds via its At-The-Market (ATM) offering during the first nine months of 2025.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management states that current funds are insufficient to complete development activities or attain profitability. The company anticipates continued net losses and negative cash flows, raising "substantial doubt" about its ability to continue as a going concern for at least twelve months without additional financing.
- Capital Needs: The company plans to fund operations through cash on hand, marketable securities, and additional equity/debt financing. Failure to secure funding could force a curtailment of development or liquidation.
- Subsequent Events: On October 8, 2025, the company closed a registered direct offering raising approximately $1.1 million in gross proceeds, issuing 678,125 shares and concurrent warrants.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, including lack of adherence to formal policies and ineffective controls over warrant accounting. Management is engaged in remediation efforts.
- Stock Repurchase: A $2.0 million stock repurchase program authorized in June 2025 has seen no repurchases as of September 30, 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.1 million raised in October 2025 combined with remaining cash/securities to fund the Phase 2 clinical trial through the next 12 months.
- Revenue Concentration: Confirm the status of the exclusive supply agreement with Cartessa Aesthetics, LLC, as product revenue dropped to zero in Q3 2025.
- Warrant Liability Volatility: Monitor the fair value of warrant liabilities ($1.97M), as changes in stock price significantly impact reported net income/loss.
- Internal Control Remediation: Review progress on fixing material weaknesses in financial reporting to ensure future financial statement reliability.
- Dilution Risk: Assess the impact of outstanding warrants (3.95M shares) and options (5.26M shares) on future share count and per-share value.